Osilodrostat for the treatment of Cushing's disease: efficacy, stability, and persistence

被引：0
|
作者：
Chabre, Olivier [1 ]
Muller, Marie [2 ]
Cristante, Justine [1 ]
Cracowski, Jean-Luc [3 ]
Gay, Emmanuel [4 ]
机构：
[1] Univ Grenoble Alpes, CHU Grenoble Alpes, CEA,UGA, Unite Mixte Rech,Serv Endocrinol,INSERM,UMR 1036, F-38000 Grenoble, France
[2] CHU Grenoble Alpes, Serv Endocrinol, Grenoble, France
[3] Grenoble Alpes Univ, Pharmacovigilance Dept, INSERM, UMR 1300,Lab HP2, Grenoble, France
[4] Univ Grenoble Alpes, CHU Grenoble Alpes, Serv Neurochirurg, Grenoble, France
来源：
LANCET DIABETES & ENDOCRINOLOGY | 2022年 / 10卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：384 / 385
页数：2
相关论文
共 50 条
  • [31] Cushing’s syndrome: a combined treatment with etomidate and osilodrostat in severe life-threatening hypercortisolemia
    Lukasz Dzialach
    Joanna Sobolewska
    Wioleta Respondek
    Agnieszka Wojciechowska-Luzniak
    Przemyslaw Witek
    Hormones, 2022, 21 : 735 - 742
  • [32] The Treatment of Cushing's Disease
    Pivonello, Rosario
    De Leo, Monica
    Cozzolino, Alessia
    Colao, Annamaria
    ENDOCRINE REVIEWS, 2015, 36 (04) : 385 - 486
  • [33] Progression of a corticotroph tumour during durable medical therapy with osilodrostat in a patient with persistent Cushing's disease
    Borawski, Bartlomiej
    Wojciechowska-Luzniak, Agnieszka
    Zielinski, Grzegorz
    Witek, Przemyslaw
    ENDOKRYNOLOGIA POLSKA, 2023, 74 (03) : 346 - 347
  • [34] Improvement in clinical features of hypercortisolism during osilodrostat treatment: findings from the Phase III LINC 3 trial in Cushing's disease
    Pivonello, R.
    Fleseriu, M.
    Newell-Price, J.
    Shimatsu, A.
    Feelders, R. A.
    Kadioglu, P.
    Tabarin, A.
    Brue, T. C.
    Geer, E. B.
    Piacentini, A.
    Pedroncelli, A. M.
    Biller, B. M. K.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2024, 47 (10) : 2437 - 2448
  • [35] Osilodrostat Is a Potential Novel Steroidogenesis Inhibitor for the Treatment of Cushing Syndrome: An In Vitro Study
    Creemers, Sara G.
    Feelders, Richard A.
    de Jong, Frank H.
    Franssen, Gaston J. H.
    de Rijke, Yolanda B.
    van Koetsveld, Peter M.
    Hofland, Leo J.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2019, 104 (08): : 3437 - 3449
  • [36] Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase
    Pivonello, Rosario
    Fleseriu, Maria
    Newell-Price, John
    Bertagna, Xavier
    Findling, James
    Shimatsu, Akira
    Gu, Feng
    Auchus, Richard
    Leelawattana, Rattana
    Lee, Eun Jig
    Kim, Jung Hee
    Lacroix, Andre
    Laplanche, Audrey
    O'Connell, Paul
    Tauchmanova, Libuse
    Pedroncelli, Alberto M.
    Biller, Beverly M. K.
    LANCET DIABETES & ENDOCRINOLOGY, 2020, 8 (09): : 748 - 761
  • [37] Medical Treatment of Cushing's Disease
    Feelders, Richard A.
    Hofland, Leo J.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2013, 98 (02): : 425 - 438
  • [38] Treatment of Cushing's disease with ketoconazole
    Mendez Perez, P.
    Barrio Castellanos, R.
    Nunez Estevez, M.
    Perez Rodriguez, C.
    Domenech, R. Hernandez
    ANALES DE PEDIATRIA, 2009, 70 (04): : 366 - 369
  • [39] Fluconazole in the treatment of Cushing's disease
    Burns, Kharis
    Christie-David, Darshika
    Gunton, Jenny E.
    ENDOCRINOLOGY DIABETES AND METABOLISM CASE REPORTS, 2016,
  • [40] Pioglitazone treatment in Cushing’s disease
    D. Barbaro
    P. Lapi
    P. Orsini
    C. Pasquini
    S. Ciaccio
    Journal of Endocrinological Investigation, 2005, 28 : 388 - 389
12345